Not Signed In - Vanda Pharmaceuticals' VEC-162 Demonstrates Positive Results In A Phase III Transient Insomnia Clinical Trial
Thu, 16 Nov 2006 08:00 AM EST
... Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced positive top-line results from the company's Phase III clinical trial evaluating VEC-162, a balanced melatonin receptor agonist, in transient insomnia. [click link for full article] ...
Related Topics
- Clinical Trials
- Insomnia
- Antithrombin III
- Stroke, Transient
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Familial Dysautonomia
- Tarceva
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Tb
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Transient tic disorder
- Transient familial hyperbilirubinemia
- Transient tachypnea - newborn
- Brain injury that results in physical, emotional, or intellectual changes or deficits
email this page
print this page
bookmark this page
feedback on this page
